Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri

@article{Dahlf2005PreventionOC,
  title={Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri},
  author={Bj{\"o}rn Dahl{\"o}f and Peter S Sever and Neil R. Poulter and Hans Wedel and DAVID G. Beevers and Mark J. Caulfield and Rory Collins and Sverre E. Kjeldsen and Arni Kristinsson and Gordon T. Mcinnes and Jesper Mehlsen and Markku S Nieminen and Eoin O’Brien and Jan {\"O}stergren},
  journal={The Lancet},
  year={2005},
  volume={366},
  pages={895-906}
}

Figures and Tables from this paper

Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension

Dahlof B, Sever PS, Poulter NR, et al . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as

Which patients would benefit the most from the perindopril-amlodipine combination?

TLDR
The combination of amlodipine and perindopril should prove particularly beneficial in patients with coronary artery disease and either hypertension or anginal symptoms, as well as elderly populations or patients with chronic kidney disease.

Blood pressure lowering therapy in older and younger hypertensive patients.

TLDR
The primary endpoint was not significantly different between the two treatment regimens at that time, at least partly explained by the premature termination of the trial, and the incidence of most of the seven secondary endpoints was significantly lower on the amlodipine-based regimen than on the atenolol- based regimen.

The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes

TLDR
In the large diabetic subgroup in the blood pressure-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial, the benefits of amlodipine-based treatment, compared with atenolol- based treatment, on the incidence of total cardiovascular events and procedures was significant and similar to that observed in the total trial population.

Comparative Study of the Efficacy of Olmesartan/Amlodipine vs. Perindopril/Amlodipine in Peripheral and Central Blood Pressure Parameters After Missed Dose in Type 2 Diabetes.

TLDR
The OLM-AML combination is safe, well tolerated, and not inferior to the combination of PER/AML in lowering CBP and CBP-derived parameters in diabetic patients and provides longer-lasting efficacy in terms of CBP reduction compared to PER/ AML.

The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-Blind Trial in Patients with Hypertension

TLDR
The combination of OLM/AMl was superior to PER/AML in reducing CSBP and other efficacy measures, including a significantly higher rate of BP normalization.

A new dimension in hypertension management with the amlodipine/perindopril combination

  • N. Poulter
  • Medicine, Biology
    Journal of hypertension
  • 2011
TLDR
Analysis of long-term BP variability provided a further explanation for the reduction of cardiovascular events with amlodipine/perindopril in ASCOT, and the combination of perindoprine and amlODipine seems an ideal logical evidence-based pair of antihypertensive agents to select.

Perindopril: a review of its use in patients with or at risk of developing coronary artery disease.

TLDR
These trials demonstrate that while perindopril, in addition to standard recommended therapy, has a potential role in preventing cardiovascular events in hypertensive patients, its role in the management of patients with stable CAD is clearly established.

Combination of Amlodipine plus Angiotensin Receptor Blocker or Diuretics in High-Risk Hypertensive Patients

TLDR
Long-term combination therapy with amlodipine plus telmisartan or amloderide plus amiloride/hydrochlorothiazide was not only well tolerated but also efficacious in reducing BP levels with acceptable control rates in the majority of hypertensive patients.
...

References

SHOWING 1-10 OF 35 REFERENCES

Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial

TLDR
The study has 80% power (at the 5% level) to detect a relative difference of 20% in CHD endpoints between the calcium channel blocker-based regimen and the β-blocker-based program and the lipid-lowering limb of the study has 90% power at the 1% level.

Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial

TLDR
The greater efficacy of lacidipine on carotid IMT progression and number of plaques per patient, despite a smaller ambulatory blood pressure reduction, indicates an antiatherosclerotic action of lacIDipine independent of its antihypertensive action.

Old antihypertensives and new diabetes

TLDR
When compared with placebo, ACE inhibition by ramipril or by the ARB, candesartan, both decrease the incidence of new diabetes, raising the hypothesis that these agents actually prevent the changes leading to insulin resistance, possibly by lessening the adverse effects of angiotensin II on the endothelium.